Systemic chemotherapy and sequential locoregional radiotherapy in initially metastatic nasopharyngeal carcinoma: Retrospective analysis with 821 cases. Issue 8 (10th March 2020)

• Record Type: Journal Article
• Authors: Huang, Tianying; Su, Ning; Zhang, Xuanye; Ma, Shuyun; Zhong, Guangzheng; Tian, Xiaopeng; Chen, Qiuyan; Tang, Linglong; Lu, Lixia; Fang, Yu; Cai, Jun; Cai, Qingqing
• Is Part Of: Head & neck. Volume 42:Issue 8(2020)
• Page Start: 1970
• Page End: 1980
• Publication Date: 2020-03-10
• Subjects: chemotherapy -- local treatment -- metastatic -- nasopharyngeal carcinoma -- radiotherapy; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.26130
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: We designed this retrospective study to explore the best treatment modality for patients with initially metastatic nasopharyngeal carcinoma (NPC). Methods: From 2008 to 2017, 821 patients were enrolled. Treatment modalities and prognostic factors were analyzed. Results: Compared with chemotherapy alone and radiotherapy‐based treatment, systemic chemotherapy‐sequential locoregional radiotherapy to the nasopharyngeal primary tumor site were associated with a significantly increased 3‐year overall survival (OS) rate (40.3%, 11.7%, and 22.9%, P < .001). The overall response rate of the paclitaxel combined with platinum and fluorouracil (TPF) regimen as first‐line chemotherapy was higher than that of the paclitaxel plus platinum (TP) regimen (78.2% vs 70.0%, P = .038). A better OS was achieved in the TPF group compared to doublet drug regimens (3‐year OS, 35.7% vs 25.3%, P < .001). Conclusions: Systemic chemotherapy‐sequential locoregional radiotherapy may prolong OS and progression‐free survival for selected patients with initially metastatic NPC.